The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The Gastroesophageal Reflux Disease Therapeutics Market Between 2026 And 2030?
The gastroesophageal reflux disease therapeutics market size has seen significant growth in recent years. It is projected to expand from $6.08 billion in 2025 to $6.42 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.6%. This historical growth can be primarily linked to the rising prevalence of gerd, the widespread adoption of proton pump inhibitors, increasing awareness regarding digestive health, the expansion of hospital pharmacies, and an expanding geriatric population.
The gastroesophageal reflux disease therapeutics market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $8.38 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.9%. This anticipated growth during the forecast period stems from factors such as advancements in drug formulations, the proliferation of e-pharmacies, the widespread use of telemedicine for gastrointestinal care, rising investments in precision medicine, and an increasing need for less invasive therapeutic options. Key trends characterizing this period are expected to encompass individualized GERD treatment strategies, the creation of innovative drug delivery mechanisms, a heightened consumer preference for over-the-counter GERD remedies, a greater emphasis on maintaining gut health and regulating the microbiome, and the incorporation of remote patient monitoring alongside telehealth services.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp
What Major Drivers Are Influencing Demand In The Gastroesophageal Reflux Disease Therapeutics Market?
The increasing use of self-medication is a significant contributor to the future growth of the gastroesophageal reflux disease therapeutics market. This practice involves individuals managing their medical conditions with drugs or other substances without seeking professional healthcare advice. Self-medication plays a crucial role in identifying and avoiding trigger foods, managing stress, and quitting smoking, all of which can considerably improve GERD symptoms. For example, in July 2024, the Proprietary Association of Great Britain (PAGB), a UK-based trade association, published data revealing that with 64 million UK residents experiencing at least one self-treatable condition in 2023, the share of GP-advised cases for over-the-counter self-care notably increased from 58% in 2023 to 75% in 2024. Concurrently, consumer confidence in utilizing these medications rose to 89%, indicating an 8-point gain compared to the previous year. Thus, the widespread adoption of self-medication is a primary driver for the gastroesophageal reflux disease therapeutics market.
Which Market Segments Are Examined In The Gastroesophageal Reflux Disease Therapeutics Market Study?
The gastroesophageal reflux disease therapeutics market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets
Subsegments:
1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents
2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents
Which Trends Are Influencing The Gastroesophageal Reflux Disease Therapeutics Market?
Leading companies in the gastroesophageal reflux disease therapeutics market are focusing on developing innovative systems, such as wireless pH-capsule reflux testing systems. These wireless pH-capsule reflux testing systems are medical devices intended for the diagnosis and monitoring of gastroesophageal reflux disease (GERD) and related conditions. For instance, in April 2023, Laborie Medical Technologies Corp., a US-based medical testing equipment manufacturing company, announced the launch of its alpHaONE system. This system is a wireless pH-capsule reflux testing system specifically engineered to diagnose gastroesophageal reflux disease (GERD). The system allows for up to 96 hours of data monitoring, providing accurate and reliable data. alpHaONE offers a distinctive solution with an ergonomic and compact design, enlarged buttons that are easy to press, and a fail-safe capsule delivery system designed to safeguard the patient’s esophagus.
Who Are The Primary Competitors In The Gastroesophageal Reflux Disease Therapeutics Market?
Major companies operating in the gastroesophageal reflux disease therapeutics market are Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited
Read the full gastroesophageal reflux disease therapeutics market report here:
Which Region Shows The Strongest Potential For Future Growth In The Gastroesophageal Reflux Disease Therapeutics Market?
North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Gastroesophageal Reflux Disease Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12058&type=smp
Browse Through More Reports Similar to the Global Gastroesophageal Reflux Disease Therapeutics Market 2026, By The Business Research Company
Gastroesophageal Reflux Disease Therapeutics Market Report 2026
Animal Gastroesophageal Reflux Disease Market Report 2026
Reflux Testing Products Market Report 2026
https://www.thebusinessresearchcompany.com/report/reflux-testing-products-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model